Kernal Biologics closes $25 million Series A financing
US development-stage mRNA-technology company Kernal Biologics today announced the completion of a $25 million Series A led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other VCs, family offices and high net worth individuals also participated in the round.
The new capital will extend Kernal’s mRNA 2.0 platform and support the filing of an investigational new drug (IND) for Kernal’s immuno-oncology candidate KR-335.
“We have closely followed the work of the Kernal Bio team over the past few years and we are excited to see them bring their mRNA technology to fruition in an area of medicine with high unmet medical need,” said Firat Ileri, managing partner of Hummingbird Ventures, adding: “Kernal Bio is building on the success stories of Moderna and Pfizer/BioNTech with legacy mRNA technologies. We are delighted to partner with them to bring this innovative approach to cancer patients.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze